Market Cap 302.01M
Revenue (ttm) 0.00
Net Income (ttm) -236.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.75
Volume 864,600
Avg Vol 1,362,794
Day's Range N/A - N/A
Shares Out 185.28M
Stochastic %K 6%
Beta 2.73
Analysts Sell
Price Target $9.14

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associ...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 760 0900
Address:
260 Arsenal Place, Suite 1, Watertown, United States
Tedsssss
Tedsssss Jun. 7 at 7:05 PM
$NMRA Rocket next week
1 · Reply
Only_Bulls
Only_Bulls Jun. 6 at 5:10 PM
$NMRA  KOASTAL COUNTDOWN We’re officially in the KOASTAL window. Guidance is Q2 and “before quarter end,” so any morning can be the morning. This is the classic pre-binary setup: price gets leaned on, sentiment gets crushed, and shares quietly transfer to people willing to hold into the headline. Once it hits, there’s no “nice entry” …it gaps and the chart becomes an afterthought. Why this one matters: KOASTAL-2/3 were optimized vs KOASTAL-1 (tighter screening, SAFER oversight, higher screen fails, better patient quality, better sites). They’ve said they’ll release both toplines plus pooled analysis together. If the PR reads clean (“met primary endpoint”), volume goes nuclear and the repricing is fast. Not advice ….just the countdown.
1 · Reply
Only_Bulls
Only_Bulls Jun. 5 at 8:59 PM
$NMRA KOASTAL setup is being slept on. May ’26 deck reiterates KOASTAL-2/3 topline in 2Q’26 and shows concrete trial upgrades vs KOASTAL-1: screen-fail 62%→71%, female 55%→64%, >400 pts in KOASTAL-2/3, and ~60% enrolled post-optimizations. Biggest tell: MGH CTNI SAFER clinician-rated screening/monitoring to verify patient appropriateness + better site selection + screening for repeat trial participants. If placebo/patient quality was the issue, this is the fix. NFA.
0 · Reply
Only_Bulls
Only_Bulls Jun. 5 at 7:14 PM
$NMRA 🔥 They’re handing out CHEAPIES again while we’re sitting in the KOASTAL window. Price getting leaned on into the catalyst? Fine. That’s how these set up. Weak hands puke, bids reload, and then one morning the headline hits and there’s no “buy button” time. KOASTAL-2/3 topline is expected any day before quarter end. Management already told the market they tightened screening, SAFER oversight, higher screen-fails, more representative enrollment, and they plan to drop both toplines + pooled analysis together. That’s not the posture of a company bracing for disaster. If you’re waiting for the chart to look perfect, you’ll be chasing the gap. I’m watching for the day this flips and shorts/hedges get steamrolled. Get your cheapies before the 💣. NFA.
0 · Reply
Kaltycoon
Kaltycoon Jun. 5 at 4:20 PM
$NMRA holding well here on a slaughter day, just please give us some freaking decent news.
0 · Reply
Xmandingo
Xmandingo Jun. 4 at 6:29 PM
$NMRA ZZZZZZZZZZZZ
0 · Reply
Mr_GA
Mr_GA Jun. 4 at 2:07 PM
$NMRA https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html
3 · Reply
Only_Bulls
Only_Bulls Jun. 3 at 5:18 AM
2 · Reply
GoosingIt
GoosingIt Jun. 2 at 6:14 PM
$NMRA What's your best guess for KOASTAL 2/3 Phase III Topline Data Release?
0 · Reply
QulckTrade
QulckTrade Jun. 1 at 6:30 PM
$NMRA if ti push to $2.X and brake out , we can see Inverse H&S , possibly back to $2.40
0 · Reply
Latest News on NMRA
Neumora Therapeutics Transcript: AGM 2026

May 27, 2026, 4:00 PM EDT - 11 days ago

Neumora Therapeutics Transcript: AGM 2026


Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)

2026-05-07T15:39:57.000Z - 4 weeks ago

Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)


Neumora Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Neumora Therapeutics Earnings release: Q1 2026


Neumora Therapeutics Slides: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Neumora Therapeutics Slides: Q1 2026


Neumora Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Neumora Therapeutics Quarterly report: Q1 2026


Neumora Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 7 weeks ago

Neumora Therapeutics Proxy statement: Proxy filing


Neumora Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 7 weeks ago

Neumora Therapeutics Proxy statement: Proxy filing


Neumora Therapeutics management to meet with Piper Sandler

2026-04-02T14:37:16.000Z - 2 months ago

Neumora Therapeutics management to meet with Piper Sandler


Neumora Therapeutics Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 2 months ago

Neumora Therapeutics Earnings Call Transcript: Q4 2025


Neumora Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 2 months ago

Neumora Therapeutics Annual report: Q4 2025


Neumora Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 2 months ago

Neumora Therapeutics Earnings release: Q4 2025


Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)

2026-03-30T11:00:07.000Z - 2 months ago

Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)


Neumora Therapeutics Slides: Corporate presentation

Mar 30, 2026, 6:30 AM EDT - 2 months ago

Neumora Therapeutics Slides: Corporate presentation


Neumora Therapeutics management to meet virtually with Needham

2026-03-02T18:05:39.000Z - 3 months ago

Neumora Therapeutics management to meet virtually with Needham


Neumora Therapeutics Slides: Corporate presentation

Feb 10, 2026, 7:00 AM EST - 4 months ago

Neumora Therapeutics Slides: Corporate presentation


Neumora Therapeutics initiated with an Outperform at Leerink

2026-01-12T10:25:32.000Z - 5 months ago

Neumora Therapeutics initiated with an Outperform at Leerink


Neumora Therapeutics Transcript: Study Result

Jan 5, 2026, 8:00 AM EST - 5 months ago

Neumora Therapeutics Transcript: Study Result


Neumora Therapeutics Press release: Study Result

Jan 5, 2026, 8:00 AM EST - 5 months ago

Neumora Therapeutics Press release: Study Result


Neumora Therapeutics Slides: Study Result

Jan 5, 2026, 8:00 AM EST - 5 months ago

Neumora Therapeutics Slides: Study Result


Neumora Therapeutics highlights 2026 pipeline strategy

2026-01-05T11:41:35.000Z - 5 months ago

Neumora Therapeutics highlights 2026 pipeline strategy


LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO

2025-11-12T13:15:37.000Z - 7 months ago

LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO

LBRX


Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)

2025-11-06T12:06:36.000Z - 7 months ago

Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)


Neumora Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Neumora Therapeutics Quarterly report: Q3 2025


Neumora Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Neumora Therapeutics Earnings release: Q3 2025


Neumora Therapeutics upgraded to Buy from Neutral at Guggenheim

2025-10-27T12:06:02.000Z - 7 months ago

Neumora Therapeutics upgraded to Buy from Neutral at Guggenheim


Neumora Therapeutics Transcript: R&D Day 2025

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Neumora Therapeutics Transcript: R&D Day 2025


Neumora Therapeutics Press release: FY 2025

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Neumora Therapeutics Press release: FY 2025


Neumora Therapeutics Slides: FY 2025

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Neumora Therapeutics Slides: FY 2025


Neumora Therapeutics’ NMRA-215 shows weight loss efficacy

2025-10-27T10:40:05.000Z - 7 months ago

Neumora Therapeutics’ NMRA-215 shows weight loss efficacy


Neumora Therapeutics to Host Virtual R&D Day on October 27

Oct 1, 2025, 7:00 AM EDT - 8 months ago

Neumora Therapeutics to Host Virtual R&D Day on October 27


Neumora Therapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Neumora Therapeutics Earnings Call Transcript: Q2 2025


Neumora Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Neumora Therapeutics Quarterly report: Q2 2025


Neumora Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Neumora Therapeutics Earnings release: Q2 2025


Neumora Therapeutics Slides: Corporate Presentation

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Neumora Therapeutics Slides: Corporate Presentation


Neumora Therapeutics Slides: Corporate Presentation

Jul 9, 2025, 4:00 PM EDT - 11 months ago

Neumora Therapeutics Slides: Corporate Presentation


Neumora Therapeutics Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing


Neumora Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings Call Transcript: Q1 2025


Neumora Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Quarterly report: Q1 2025


Neumora Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings release: Q1 2025


Neumora Therapeutics Slides: Corporate Presentation

May 12, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics Slides: Corporate Presentation


Neumora Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing


Neumora Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing


Neumora Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing


Neumora Therapeutics Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Neumora Therapeutics Earnings Call Transcript: Q4 2024


Neumora Therapeutics Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Neumora Therapeutics Annual report: Q4 2024


Neumora Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Neumora Therapeutics Earnings release: Q4 2024


Tedsssss
Tedsssss Jun. 7 at 7:05 PM
$NMRA Rocket next week
1 · Reply
Only_Bulls
Only_Bulls Jun. 6 at 5:10 PM
$NMRA  KOASTAL COUNTDOWN We’re officially in the KOASTAL window. Guidance is Q2 and “before quarter end,” so any morning can be the morning. This is the classic pre-binary setup: price gets leaned on, sentiment gets crushed, and shares quietly transfer to people willing to hold into the headline. Once it hits, there’s no “nice entry” …it gaps and the chart becomes an afterthought. Why this one matters: KOASTAL-2/3 were optimized vs KOASTAL-1 (tighter screening, SAFER oversight, higher screen fails, better patient quality, better sites). They’ve said they’ll release both toplines plus pooled analysis together. If the PR reads clean (“met primary endpoint”), volume goes nuclear and the repricing is fast. Not advice ….just the countdown.
1 · Reply
Only_Bulls
Only_Bulls Jun. 5 at 8:59 PM
$NMRA KOASTAL setup is being slept on. May ’26 deck reiterates KOASTAL-2/3 topline in 2Q’26 and shows concrete trial upgrades vs KOASTAL-1: screen-fail 62%→71%, female 55%→64%, >400 pts in KOASTAL-2/3, and ~60% enrolled post-optimizations. Biggest tell: MGH CTNI SAFER clinician-rated screening/monitoring to verify patient appropriateness + better site selection + screening for repeat trial participants. If placebo/patient quality was the issue, this is the fix. NFA.
0 · Reply
Only_Bulls
Only_Bulls Jun. 5 at 7:14 PM
$NMRA 🔥 They’re handing out CHEAPIES again while we’re sitting in the KOASTAL window. Price getting leaned on into the catalyst? Fine. That’s how these set up. Weak hands puke, bids reload, and then one morning the headline hits and there’s no “buy button” time. KOASTAL-2/3 topline is expected any day before quarter end. Management already told the market they tightened screening, SAFER oversight, higher screen-fails, more representative enrollment, and they plan to drop both toplines + pooled analysis together. That’s not the posture of a company bracing for disaster. If you’re waiting for the chart to look perfect, you’ll be chasing the gap. I’m watching for the day this flips and shorts/hedges get steamrolled. Get your cheapies before the 💣. NFA.
0 · Reply
Kaltycoon
Kaltycoon Jun. 5 at 4:20 PM
$NMRA holding well here on a slaughter day, just please give us some freaking decent news.
0 · Reply
Xmandingo
Xmandingo Jun. 4 at 6:29 PM
$NMRA ZZZZZZZZZZZZ
0 · Reply
Mr_GA
Mr_GA Jun. 4 at 2:07 PM
$NMRA https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html
3 · Reply
Only_Bulls
Only_Bulls Jun. 3 at 5:18 AM
2 · Reply
GoosingIt
GoosingIt Jun. 2 at 6:14 PM
$NMRA What's your best guess for KOASTAL 2/3 Phase III Topline Data Release?
0 · Reply
QulckTrade
QulckTrade Jun. 1 at 6:30 PM
$NMRA if ti push to $2.X and brake out , we can see Inverse H&S , possibly back to $2.40
0 · Reply
SPuffet
SPuffet Jun. 1 at 3:30 PM
$NMRA this goes nowhere prior to readout data; don’t be fooled; whoever enters now will face the same binary risk; upside is great (+200% or more) but downside (-100% or more) is equally possible.
0 · Reply
md725
md725 Jun. 1 at 2:56 PM
$NMRA BOOM ! Huge Purchase by H Fund.
2 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Jun. 1 at 1:43 PM
$NMRA Any day now ........ on positive news this should go back to $15+ which was the price prior to Koastal 1 readout.
2 · Reply
Only_Bulls
Only_Bulls Jun. 1 at 3:19 AM
$NMRA As we head into June…We are officially in the KOASTAL window now. They’ve guided KOASTAL-2 and KOASTAL-3 topline for Q2, and they’ve been consistent that it’s coming before quarter-end. That means any day from here forward can be “the day.” This thing has been sitting down here priced like nobody believes… and that’s exactly why the move can be violent when the headline hits. You don’t need a slow grind to $3 first..you need one clean press release and the entire tape reprices. In the RBC chat they hammered the “we fixed the trial” narrative: stricter screening, SAFER oversight, higher screen-fail rates, more representative enrollment. They plan to drop both toplines plus pooled analysis together. They’re not acting like a company that’s hiding. They’re acting like a company ready to defend the dataset. If you’re waiting for a perfect chart, you’re going to be late. If you’re waiting for a warning siren before the release… the siren IS the release. Not advice. Just reality:
0 · Reply
Only_Bulls
Only_Bulls May. 28 at 6:43 PM
$NMRA Could all the analysts be wrong? I guess that’s a decision we each have to make but my moneys on a win by the end of June. NFA
2 · Reply
SPuffet
SPuffet May. 28 at 4:01 PM
$NMRA and when they were halfway there they were neither up nor down
0 · Reply
Only_Bulls
Only_Bulls May. 28 at 4:19 AM
$NMRA Strong Buy…
2 · Reply
Kaltycoon
Kaltycoon May. 27 at 9:11 PM
$NMRA let’s gap back into our beloved rising channel tomorrow
0 · Reply
InvestorCG
InvestorCG May. 27 at 8:13 PM
$NMRA Assuming everything passed?
1 · Reply
Only_Bulls
Only_Bulls May. 27 at 12:51 AM
$NMRA In case you didn’t know. https://ir.neumoratx.com/events/event-details/annual-meeting-0
1 · Reply
Only_Bulls
Only_Bulls May. 27 at 12:44 AM
0 · Reply
Kaltycoon
Kaltycoon May. 23 at 1:58 AM
$NMRA when results?! Study completed.
0 · Reply